Antiepileptogenic and anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model

Epilepsy Research

Volumn 89, Issue 2-3, 2010, Pages 360-364

  Ohno, Yukihiro ^a   Ishihara, Shizuka ^a   Terada, Ryo ^a   Serikawa, Tadao ^b   Sasa, Masashi ^c  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

Antiepileptic drugs; Epileptogenesis; Kindling; Levetiracetam; Pentylenetetrazole

Indexed keywords

ETIRACETAM; PENTETRAZOLE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; KINDLING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; TREATMENT RESPONSE;

ANIMALS; ANTICONVULSANTS; CONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INJECTIONS, INTRAPERITONEAL; KINDLING, NEUROLOGIC; MALE; MICE; MICE, INBRED STRAINS; PENTYLENETETRAZOLE; PIRACETAM; SEIZURES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 77951296418     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.01.011     Document Type: Article

References (23)

1. Bastlund J.F., Berry D., Watson W.P. Pharmacological and histological characterisation of nicotine-kindled seizures in mice. Neuropharmacology 2005, 48:975-983.
2. Ben-Menachem E., Falter U. Efficacy and tolerability of levetiracetam 3000mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000, 41:1276-1283. European Levetiracetam Study Group.
3. Bouwman B.M., van Rijn C.M. Effects of levetiracetam on spike and wave discharges in WAG/Rij rats. Seizure 2004, 13:591-594.
4. Brandt C., Glien M., Gastens A.M., Fedrowitz M., Bethmann K., Volk H.A., Potschka H., Löscher W. Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. Neuropharmacology 2007, 53:207-221.
5. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000, 55:236-242.
6. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., Lu Z. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006, 66:1654-1660. N159 Study Group.
7. Gower A.J., Hirsch E., Boehrer A., Noyer M., Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995, 22:207-213.
8. Gu J., Lynch B.A., Anderson D., Klitgaard H., Lu S., Elashoff M., Ebert U., Potschka H., Löscher W. The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur. J. Neurosci. 2004, 19:334-345.
9. Husum H., Bolwig T.G., Sánchez C., Mathé A.A., Hansen S.L. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav. 2004, 5:204-215.
10. Ji-qun C., Ishihara K., Nagayama T., Serikawa T., Sasa M. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs. Epilepsia 2005, 46:1362-1370.
11. Kaminski R.M., Matagne A., Leclercq K., Gillard M., Michel P., Kenda B., Talaga P., Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008, 54:715-720.
12. Kaminski R.M., Gillard M., Leclercq K., Hanon E., Lorent G., Dassesse D., Matagne A., Klitgaard H. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of Levetiracetam. Epilepsia 2009, 50:1729-1740.
13. Klitgaard H., Matagne A., Gobert J., Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998, 353:191-206.
14. Löscher W., Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 1993, 232:147-158.
15. Löscher W., Hönack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 1998, 284:474-479.
16. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9861-9866.
17. Matveeva E.A., Vanaman T.C., Whiteheart S.W., Slevin J.T. Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes. Epilepsia 2008, 49:1749-1758.
18. Mody I. The molecular basis of kindling. Brain Pathol. 1993, 3:395-403.
19. Morimoto K., Fahnestock M., Racine R.J. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog. Neurobiol. 2004, 73:1-60.
20. Ohno Y., Ishihara S., Terada R., Kikuta M., Sofue N., Kawai Y., Serikawa T., Sasa M. Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling. Biochem. Biophys. Res. Commun. 2009, 390:415-420.
21. Sasa M. A new frontier in epilepsy: novel antiepileptogenic drugs. J. Pharmacol. Sci. 2006, 100:487-494.
22. Sato M., Racine R.J., McIntyre D.C. Kindling: basic mechanisms and clinical validity. Electroencephalogr. Clin. Neurophysiol. 1990, 76:459-472.
23. Yan H.D., Ji-qun C., Ishihara K., Nagayama T., Serikawa T., Sasa M. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia 2005, 46:1170-1177.